From survival to survivorship: Late side effects become an issue in high-grade glioma

Expert Review of Neurotherapeutics

Volumn 10, Issue 10, 2010, Pages 1493-1495

  Lawrence, Yaacov R ^a   Shi, Wenyin ^a   Dicker, Adam P ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

brain tumor; cognitive decline; glioma; radiation therapy; side effects

Indexed keywords

DOXORUBICIN; TEMOZOLOMIDE;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; EDITORIAL; GLIOBLASTOMA; GLIOMA; HUMAN; NEUROTOXICITY; QUALITY OF LIFE;

BRAIN NEOPLASMS; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE PROGRESSION; GLIOMA; HUMANS; MOLECULAR TARGETED THERAPY; SURVIVAL RATE; TIME FACTORS;

EID: 77958018930     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.123     Document Type: Editorial

References (35)

1. DeAngelis LM. Brain tumors. N. Eng. J. Med. 344, 114-123 (2001).
2. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 64, 479-489 (2005).
3. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Eng. J. Med. 352, 987-996 (2005).
4. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009).
5. Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl Cancer Inst. 85, 704-710 (1993).
6. Krex D, Klink B, Hartmann C et al. Long-term survival with glioblastoma multiforme. Brain 130, 2596-2606 (2007).
7. Weller M, Felsberg J, Hartmann C et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: A prospective translational study of the German Glioma Network. J. Clin. Oncol. 27, 5743-5750 (2009).
8. Liu Y, Shete S, Etzel CJ et al. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J. Clin. Oncol. 28, 2467-2474 (2010).
9. Felsberg J, Rapp M, Loeser S et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin. Cancer Res. 15, 6683-6693 (2009).
10. Grossman SA, Ye X, Piantadosi S et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin. Cancer Res. 16, 2443-2449 (2010).
11. al-Mefty O, Kersh JE, Routh A, Smith RR. The long-term side effects of radiation therapy for benign brain tumors in adults. J. Neurosurg. 73, 502-512 (1990).
12. Armstrong CL, Gyato K, Awadalla AW, Lustig R, Tochner ZA. A critical review of the clinical effects of therapeutic irradiation damage to the brain: The roots of controversy. Neuropsychol. Rev. 14, 65-86 (2004).
13. Balducci M, Mattiucci GC, Dinapoli N et al. Impact of dose and volume on the tolerance of central nervous system. Rays 30, 189-195 (2005).
14. Chong VF, Khoo JB, Chan LL, Rumpel H. Neurological changes following radiation therapy for head and neck tumours. Eur. J. Radiol. 44, 120-129 (2002).
15. Lawrence YR, Li XA, el Naqa I et al. Radiation dose-volume effects in the brain. Int. J. Radiat. Oncol. Biol. Phys. 76, S20-S27 (2010).
16. Armstrong C, Ruffer J, Corn B, DeVries K, Mollman J. Biphasic patterns of memory deficits following moderate-dose partial-brain irradiation: Neuropsychologic outcome and proposed mechanisms. J. Clin. Oncol. 13, 2263-2271 (2995).
17. Movsas B. Phase III study of prophylactic cranial irradiation (PCI) versus observation in patients with stage III non-small cell lung cancer (NSCLC): Neurocognitive and quality of life (QOL) analysis of RTOG 0214. In: Annual Meeting of American Society for Radiation Oncology, Chicago, IL, USA, 1-5 November 2009.
18. Douw L, Klein M, Fagel SS et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: Long-term follow-up. Lancet Neurol. 8, 810-818 (2009).
19. Brown RT, Madan-Swain A, Walco GA et al. Cognitive and academic late effects among children previously treated for acute lymphocytic leukemia receiving chemotherapy as CNS prophylaxis. J. Pediatr. Psychol. 23, 333-340 (1998).
20. Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 10, 293-310 (2004).
21. Ellenberg L, McComb JG, Siegel SE, Stowe S. Factors affecting intellectual outcome in pediatric brain tumor patients. Neurosurgery 21, 638-644 (1987).
22. Correa DD, DeAngelis LM, Shi W, Thaler H, Glass A, Abrey LE. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62, 548-555 (2004).
23. Harder H, Holtel H, Bromberg JE et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62, 544-547 (2004).
24. Schlegel U, Pels H, Oehring R, Blumcke I. Neurologic sequelae of treatment of primary CNS lymphomas. J. Neurooncol. 43, 277-286 (1999).
25. Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: A review of published studies and recommendations for future research. J. Clin. Oncol. 25, 2455-2463 (2007).
26. Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin. Neuropsychol. 20, 76-89 (2006).
27. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: An international perspective from the Venice cognitive workshop. Ann. Oncol. 19, 623-629 (2008).
28. Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol. 18, 1481-1491 (2000).
29. Chaichana KL, Halthore AN, Parker SL et al. Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. J. Neurosurg. DOI: 10.3171/2010.4.JNS091340 (2010) (Epub ahead of print).
30. Taphoorn MJ, Stupp R, Coens C et al. Health-related quality of life in patients with glioblastoma: A randomised controlled trial. Lancet Oncol. 6, 937-944 (2005).
31. Hottinger AF, Yoon H, DeAngelis LM, Abrey LE. Neurological outcome of long-term glioblastoma survivors. J. Neurooncol. 95, 301-305 (2009).
32. Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 116(17), 3988-3999 (2010).
33. Lawrence YR, Wang M, Dicker A et al. Acute neurological toxicity (NT) and long-term outcomes in high-grade glioma RTOG trials. J. Clin. Oncol. 28(Suppl. 1), abstract 2037 (2010).
34. Baschnagel A, Wolters P, Camphausen K. Neuropsychological testing and biomarkers in the management of brain metastases. Radiat. Oncol. 3, 26 (2008).
35. Falleti MG, Maruff P, Collie A, Darby DG. Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals. J. Clin. Exp. Neuropsychol. 28, 1095-1112 (2006).